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RESEARCH ARTICLE
Patient participation in decision-making about cardiovascular preventive
drugs – resistance as agency
Josabeth Hultberga and Carl Edvard Rudebeckb
aPrimary Care and Department of Medical and Health Sciences, Link€oping University, Norrk€oping, Sweden; bResearch Unit, Kalmar
County Council, Sweden, Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway
ABSTRACT
Objective: The aim of the study was to describe and explore patient agency through resistance
in decision-making about cardiovascular preventive drugs in primary care.
Design: Six general practitioners from the southeast of Sweden audiorecorded 80 consultations.
From these, 28 consultations with proposals from GPs for cardiovascular preventive drug treat-
ments were chosen for theme-oriented discourse analysis.
Results: The study shows how patients participate in decision-making about cardiovascular pre-
ventive drug treatments through resistance in response to treatment proposals. Passive modes
of resistance were withheld responses and minimal unmarked acknowledgements. Active modes
were to ask questions, contest the address of an inclusive we, present an identity as a non-drug-
taker, disclose non-adherence to drug treatments, and to present counterproposals. The active
forms were also found in anticipation to treatment proposals from the GPs. Patients and GPs
sometimes displayed mutual renouncement of responsibility for decision-making. The decision-
making process appeared to expand both beyond a particular phase in the consultations and
beyond the single consultation.
Conclusions: The recognition of active and passive resistance from patients as one way of exert-
ing agency may prove valuable when working for patient participation in clinical practice, educa-
tion and research about patient–doctor communication about cardiovascular preventive
medication. We propose particular attentiveness to patient agency through anticipatory resist-
ance, patients’ disclosures of non-adherence and presentations of themselves as non-drugtakers.
The expansion of the decision-making process beyond single encounters points to the import-
ance of continuity of care.
KEY POINTS
Guidelines recommend shared decision-making about cardiovascular preventive treatment. We
need an understanding of how this is accomplished in actual consultations.
This paper describes how patient agency in decision-making is displayed through different
forms of resistance to treatment proposals.
 The decision-making process expands beyond particular phases in consultations and beyond
single encounters, implying the importance of continuity of care.
 Attentiveness to patient participation through resistance in treatment negotiations is war-
ranted in clinical practice, research and education about prescribing communication.
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Parallell to an increasing demand for patient participa-
tion in health care is an increasing use of preventive
drugs. Cardiovascular prevention has become a major
task for primary care. Guidelines state at what levels of
risk preventive drugs are recommended, but also
advocate risk assessments to be the basis of shared
decisions [1,2]. Although often advocated for the sake
of outcome, patient participation in decision-making
has an ethical value in its own right.
Swedish law mandates patient participation in
health care through information and sharing of deci-
sions between patients and physicians. The communi-
cation of risk in health care is considered to be
problematic as risk statistics are often misunderstood,
by physicians as well as laymen [3]. To obtain shared
decisions, patients and physicians need to mutually
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engage in meaningful conversations and have access
to individualised evidence in formats they can under-
stand [4]. They also need to decide who decides, and
to be aware of on what grounds physicians and
patients base their respective decisional authority [5,6].
Tools to evaluate physicians’ communication skills
with regard to shared decision-making assess their
competences to involve patients in decisions [7]. The
preoccupation with the physician’s skills solely, infers
that for patient participation to occur, the patient
needs to be invited by the physician.
Contrary to such assumptions, conversation analyt-
ical studies have shown that patients do participate
actively and uninvited in decision-making [8–10].
Unlike interview-based research, conversational ana-
lysis and other interactional analytical methods are
used to study naturally occurring social interaction
such as clinical encounters.
Here, the analytical focus is neither on the GPs’ nor
the patients’ descriptions, but on their actions as par-
ticipants in communication: their display of their sense
making of what goes on, through their use of lan-
guage in interaction [11]. Theme-oriented discourse
analysis takes into account both the micro level of
detailed features of talk, and a wider context, includ-
ing the level of whole encounters. It combines the
analytical themes from studies of naturally occuring
human interaction, such as the display of agency in
decision-making, with the focal themes of concern for
the profession, such as shared decision-making.
Acting as a decisional agent has been described as
“to have choices and the competencies to act on
them” [12]. Patients exert agency when they influence
or make decisions about their health care.
An acceptance to a proposal is the normative pre-
ferred response, in everyday social interaction [13], as
well as in health care settings [8–10,14]. When a treat-
ment proposal is not readily followed by uptake from
the patient, the interaction takes on the form of a
negotiation with collaborative efforts from the partici-
pants to reach a mutually agreed decision. In spite of
the negative ring to the word, resistance from patients
to treatment proposals is one way to accomplish their
legitimate agency in decision-making, which is a pre-
requisite for shared decision-making and patient
participation.
Dispreferred responses are potentially face threaten-
ing in all interaction, and not specific for patients
responding to physicians’ treatment proposals [15].
Signals of potential disagreements in general conversa-
tions tend to be hedged and subtle, guided by polite-
ness strategies, and include silences, hesitations,
requests for clarification and weakly stated agreements
[13,16].
Previous studies from health care settings (general
internal medicine, oncology and pediatrics) have
shown the same mechanisms at play. Patient resist-
ance here was shown to be displayed through with-
held responses and weak agreements (passive
resistance), counterproposals and questions (active
resistance) [8–10].
Shared decision-making is called for in guidelines
for cardiovascular prevention. Although patient partici-
pation in decision-making through various forms of
resistance to proposals has been described in other
settings, there is a paucity of studies of actual clinical
encounters where decisions about cardiovascular pre-
ventive drugs are being made.
Aim
The aim was to describe and explore patient agency
through resistance in decision-making about cardiovas-
cular preventive drugs.
Materials and methods
The material was collected within a larger project with
the overarching aim to explore how cardiovascular risk
and recommendations for medication to prevent car-
diovascular disease is contextualised in actual
clinical encounters. Data were selected from 80
patient–GP–encounters in primary care in the south-
east of Sweden, audiorecorded 2008–2010.
GPs were recruited through a brief e-mail invitation
to all GPs in the area. Those who responded with an
interest to participate were given further information
by author JH. Six GPs participated after written con-
sent, see Table 1 for characteristics.
They were equipped with a digital recording device,
and administred inclusion of patients and recordings.
The authors were not present during data collection.
Adult patients, able to communicate in Swedish with-
out an interpreter, were included after verbal and writ-
ten consent.
The GPs were instructed to ask all patients with
scheduled appointments during 1 or 2 days, with no
prior selection of specific complaints or expected rea-
sons for the patient’s visit. This was to ensure the
Table 1. GP characteristics.
Age 41–64
Years in practice 12–36
Male/female 3/3
Rural/urban 3/3
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capture of all talk about cardiovascular preventive
drugs, also that occurring en passant in visits for other
reasons.
The recordings were transcribed verbatim by a sec-
retary, and refined by author J.H., according to conver-
sational analytical convention [11]. For transcription
symbols, see Table 2.
J.H. performed the initial sorting of the data.
Sequences involving treatment proposals from GPs
concerning cardiovascular preventive drugs were
selected for further analysis. They included suggestions
for new prescriptions, changes of dose, stopping medi-
cation, and the proposal for no change. Within these
sequences, all instances where patients did not
promptly accept the GP’s proposal were selected.
Different ways for patients to resist proposals were
related to previous findings about patient resistance as
agency [8,9], and other interactional phenomena con-
cerning agency in decision-making [10,16–18]. As pre-
viously described, physicians treat patient acceptance
of treatment as necessary to proceed to the next activ-
ity [8,9,19]. All other responses from patients to GPs’
proposals than prompt acceptance were met with
interactional work from the GPs in pursuit of accept-
ance from the patients. Such reactions from the GPs
were regarded as indications of patient resistance.
Responses from the GPs included intensifications and
modifications of their initial proposal. Intensification
was accomplished through provision of more informa-
tion, rhetorical reinforcement, such as change of fram-
ing, addition of arguments, and the invocation of
external authorities such as hospital doctors, guide-
lines or the medical expert community in general.
Modifications included postponement of decision and
adjustments according to objections brought forth by
patients, including their counterproposals.
The descriptions of resistance were refined, dis-
cussed by the authors and brought back to the empir-
ical examples for further definition. Finally we went
back to the whole encounters to get an overview of
the findings in their context.
The analysis deals with the intersection between
two themes: the general interactional concepts of
resistance and agency, and the clinically relevant focal
theme of decision-making about prescribing cardiovas-
cular preventive drugs [11].
Results
35 out of the 80 encounters concerned cardiovascular
prevention. 28 of the 35 encounters contained a treat-
ment proposal, and of these 18 contained instances
with resistance from patients to treatment proposals
from GPs. We describe seven different types of resist-
ance, illustrated by transcribed excerpts translated
from Swedish into English. See Supplementary
Appendix online for original transcripts. The encoun-
ters are referred to with GP coded with letters A–F
and the patients numbered in consecutive order.
Withheld response
Silence, even very brief, from the patient following a
treatment proposal from the GP is interactionally
handled as withholdment of acceptance.
Excerpt 1: F05
01 D: pt cause now you’ve taken it for a month
02 right
03 P: a yes h a month or five weeks
04 or what it was
05 D: yes that’s right
06 (2.9)
07 D: an’ then we oughta have seen effect (.) fully
08 from it
09 (2.4)
10 D: pt ha let’s see
11 (1.0)
12 D: pt the alternative is to add a
13 e-medicine
14 (1.7)
15 D: but (.) I think it’s better
16 to raise this
17 P: yes please
This excerpt was preceeded by a proposal from the
GP to raise the dose of an antihypertensive drug,
which the patient initially did not provide acceptance
to. Her immediate response in the turn after the pro-
posal to raise the dose is to ask “to one and half tab-
lets then”, treated by the GP as a non-acceptance of
the proposal, displayed by her continued argumenta-
tion that they should have seen the full effect by now.
Table 2. Transcription conventions.
UPPERCASE loud talk
emphatic with emphatic stress
she said [that overlapping talk starting at [[right
(xxx) undecipherable talk
¼well but no pause between turns, latching
(.) micropause (less than 1/4 s)
(2.0) timed pause (here: 2.0 s)
ye:s lengthening of a sound
tra- speaker interupts herself in word
in case– speaker leaves utterance incomplete
now speech in low volume (“sotto voce”)here laughter in speaker’s voice
((phone rings)) comments
h exhalation
.ah spoken on inhalation
pt, mt smacking, clicking sound
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The patient continues to withhold acceptance, with
long pauses in lines 6 and 9. In line 12, the GP
presents the alternative to add another medicine,
framing it as a choice between that and a raised dose,
again met with silence from the patient. When the GP,
within the new framing, proposes a raised dose in line
15, the patient accepts and they go on to the practi-
calities of prescription and follow-up arrangements.
Minimal unmarked acknowledgement, identity as
non-drugtaker, contest address
The following excerpt contains examples of different
forms of resistance. It is also illustrative of a typical
cardiovascular preventive treatment discussion in our
data, with its orientation towards measurable values,
such as blood pressure, rather than numerical risk esti-
mates, or other explicit assessments, of cardiovascular
risk. There were no examples in our data of the use of
SCORE charts or other decision aids with a quantifica-
tion of the risk.
Excerpt 2: B05
01 D: when I see this value that is a little
02 elevated then I’d like considering that
03 you have a diabetes and have heart problems
04 and so forth and that it runs in the family
05 too put you on (.) eh lipid lowering medication
06 P: mhm
07 D: that one takes at night then
08 P: mm
09 D: and it is like an extra protection then
10 P: mm
The treatment proposal is backed up with argu-
ments enhancing acceptance as the preferred response.
The patient gives minimal acknowledgements without
delay. It is not treated as acceptance by the GP who
adds information in line 7 and motivates it in line 9, still
with minimal response from the patient. The GP modi-
fies the framing with acknowledgements about the
patient’s good habits building the argument that it is
not enough, before repeating the proposal with
emphasis in lines 18–21. The patient continues to
respond minimally until the GP stresses the elevated
value in line 21, to which she responds with a question.
18 D: ehm but then one sh-shall add some
19 medication too when one sees that it
20 P: mm
21 D: after all is¼
22 P: ¼what what’s that value then
The GP states the patient’s cholesterol value and
that it is too high, reinforcing the proposal that is
repeated in lines 33–34. The patient continues to
respond minimally to the GPs’ arguments, and the deci-
sion-making process is not proceeding. In line 39, the
patient repeats her minimal response ending with
“hm”. Here the GP changes footing, leaves her line of
argumentation and asks what the patient thinks about
it, which turns their communication in a new direction.
31 D: and the desirable level is below zero point six
32 P: ah ye:s
33 D: .hhm so that’s why I think we ought to
34 add (.) another tablet then
35 P: mm
36 D: to lower the blood lipids
37 P: mm
38 D: further then
39 P: mm mm .hhm
40 D: but what do you say about that
41 P: eh well I’m not all that
42 fond of medicines
43 D: no
44 P: but of course if you judge it
45 P: like that then I hav–
46 D: yes today one has eh eh one considers
47 that one has some extra protection
48 P: mm
49 D: when one has diabetes
50 P: mm
51 D: and heart problems
52 P: mm (.)
53 D: then one has some to gain from it
54 P: but one can try it and see
55 if i:t i- make- gives an effect
56 D: absolutely
57 we follow it up
58 P: yes
The patient’s response in lines 41–42: “I’m not all
that fond of medicines” is mitigated by a tone of
laughter in her voice, signalling that she is delivering a
dispreferred response. It constitutes continued resist-
ance. She presents herself as someone – an identity
marker – not prone to take medicines.
The address, a tentative inclusive “we”, in the final
proposal in lines 33–34 is contested by the patient in
lines 44–45: “if you … I hav– … ”. She opens for an
acceptance of the treatment proposal, but renounces
the responsibility for the decision and puts it with the
GP, contesting the inclusive we from the GP.
The GPs’ “one considers” in line 46 in response to
the patients placement of responsibility on her,
detaches her from personal responsibility and passes it
on to an unspecified “one”; the medical expert com-
munity in general.
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The agent responsible for the decision is under
negotiation here, as well as the treatment decision.
The decision to treat is reached when the patient
accepts both the proposal modified according to her
conditions (to have it followed up), and the partial
responsibility for the decision in the negotiated deci-
sional agent “we”.
Ask questions
Patients’ questions in immediate response to treat-
ment proposals were seen in Excerpt 1: (raise the
dose) “to one and a half, then”, and in Excerpt 2:
“what’s that value then”. To ask questions was the
most common form of resistance in our data, with
instances from all GPs.
Excerpt 3: E21
01 D: (:) I’d like us to actually add
02 one more one blood pressure tablet and that
03 may sound like a lot cause you already have
three
04 P: yeah what model
05 D: yes it is another
06 model [than those yes another variant
07 P: [yet a model
08 P: ah yes
09 D: cause it eh it’s no use increasing
10 the dose of those you already have
Here the patient responds with a question about
what “model” of drug the GP proposes. By doing so,
he withholds acceptance. He also makes himself
accountable as a decision-maker through claiming
information on which to base a possible final decision.
The GP not only answers the question, but also pro-
vides more information, reinforcing the line of argu-
mentation for his proposal. The patient’s question is
not an explicit questioning of the treatment proposal
but it still challenges it. By asking a clarifying neutral
question the patient withholds acceptance, sets the
agenda, and claims knowledge relevant for an even-
tual decision, thereby displaying agency in the deci-
sion-making.
Counterproposals
Counterproposals were seen as a response from the
patient in the turn after a treatment proposal, but also
like in this example, within the context of evaluating
the treatment in a follow-up visit, before an explicit
treatment proposal from the GP. Counterproposals
included suggestions to change doses, to stop medica-
tion, or to postpone the decision, typically with the
proposal for diet or exercise as an alternative to the
medication proposed by the GP. The counterproposals
were sometimes backed up with reference to a non-
present authority such as advice or assessments from
other health care professionals, and sometimes with
the expression of an identity as someone who doesn’t
take medication.
In Excerpt 4, the GP introduces the topic of treating
the blood pressure, as a means to prevent stroke and
dementia, and the patient responds with talk about
physical exercise.
Excerpt 4: A06
01 D: and the treatment for that is really
02 what we’re doing here that is to
03 treat your blood pressure then
04 P: mm (.) and exercise and so on
The patient accounts for her physical activity and
that it makes her feel well. She spontaneously evalu-
ates the medication, saying that she thinks it is work-
ing well. Here she displays an interpretation of the
situation as an evaluation of the blood pressure treat-
ment in which she includes both medication and exer-
cise. When she describes her present social situation
with more spare time, the GP returns to the topic of
physical exercise, displaying an acceptance of the sug-
gestion from the patient that the treatment they are
following up is the combination of drug treatment,
and physical exercise.
185 D: an’ then perhaps one has some more time
186 to get in order with the exercise and so on
187 P: yes exactly so all I want is to
188 continue with it now so I’ll see
189 D: mm
190 P: or continue I’d rather want
191 that it would be possible to taper it down
192 if one doesn’t need (.)
193 but perhaps one doesn’t do (.) that at all
The patient responds with a proposal to stop or at
least lower the dose of the medication. It comes
before the blood pressure has been measured and
anticipates a proposal from the GP to continue or
increase the medication. After assessing the blood
pressure, the GP proposes to continue with medication
without changes, which the patient accepts.
Disclosure of non-adherence
Disclosures from patients that they do not take the
medication as prescribed came in response to pro-
posals to continue without change, and in situations
where treatments were evaluated. In return visits, like
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in Excerpt 4, patients often displayed an understand-
ing of the situation as an evaluation of on-going treat-
ment and anticipated a forthcoming proposal for
continued medication.
In the beginning of encounter C01 the patient asks
to have his cholesterol value measured and says that
he is out of tablets. The GP responds with an offer to
issue a prescription and asks if there are any problems
with the medication. The patient answers that he
doesn’t have any side effects, that he used to have
problems remembering the tablets, but has made it a
habit now, before revealing that he now deliberately
has stopped taking them before this appointment. He
displays an understanding of cholesterol lowering
treatment as possibly temporary with long-lasting
effects that he requests a test to evaluate.
Excerpt 5: C01
01 P: but now it’s been over a week
02 since I’ve taken any ya know
03 D: aha that was a bit of a pity perhaps
04 it’s difficult to take the test then I think
05 P: mm
06 D: perhaps you’d better start over
07 an’ come [back
08 P: [I don’t have any
09 D: no I think no but I’ll write you a prescription
The initial testing of waters from the patient about
being out of tablets and wanting to test his choles-
terol to see if he could do without medication, was
not taken up by the GP. When he again says that he is
out of tablets, and has not taken any for over a week,
the GP makes the connection between the request to
have a test and the disclosure about not taking the
medication. He turns the request down with a pro-
posal for continued treatment, and a test as an evalu-
ation of it, which the patient accepts. The agreement
here is to postpone the definitive decision.
Discussion
Principal findings
We studied decision-making in 28 consultations where
GPs proposed cardiovascular preventive drug treat-
ments and found patient resistance to treatment pro-
posals in the forms of withheld response, minimal
acknowledgement, questions, contest of ambiguous
address, counterproposals, expressions of identity as
non-drugtaker and revelations of non-adherence.
Through their resistance patients exerted agency with
influence on decisions, and in the case of contested
inclusive “we” also influence on who became the deci-
sion-maker.
Resistance was found in response to treatment pro-
posals. Some forms of resistance also occurred before
proposals from the GPs. Such anticipatory resistance
was revelations of non-adherence, counterproposals,
questions, and the expression of identity as non-
drugtaker.
One modification of the treatment proposal from
the GP in response to patient resistance was to post-
pone the prescribing decision.
Strengths and weaknesses
The dataset is large, and rich in relevant content. Yet,
our list of different modes of patient resistance should
not be regarded as definite or completely exhaustive.
There may be others, that are either too infrequent to
be found in our data, or that only exist in other
settings.
Data were collected 6–8 years ago, but we consider
it still useful for the purpose of the study. An approach
based on an assessment of cardiovascular risk includ-
ing recommendations to use risk assessment tools, is
in line with the national guidelines at the time, as well
as the current European guidelines for primary preven-
tion of cardiovascular disease [1,2].
The study includes both primary and secondary pre-
vention. It is not always legible which from data. We
chose not to try to select pure primary prevention for
this analysis. It makes the results less specific and
transferable to either primary or secondary prevention.
On the other hand, this is “the messy clinical reality”,
in which patients and GP’s meet, and where demarka-
tions between primary and secondary prevention are
not always clear-cut.
GPs that opted to participate were experienced.
They were probably more confident about their con-
sultation skills than the average GP, although the
opposite is a theoretical driver for participation, in a
quest to learn. Their presumed experience and good
communication skills are not necessarily drawbacks,
but may serve to enhance and elicit patient agency.
The GPs enrolled the patients. They chose when to
participate, with knowledge in advance about which
patients were booked. We have no information about
patients who declined participation, nor if there were
eligible patients not asked by the GPs. Thus, there is a
possible selection of patients, whom the GPs felt com-
fortable to communicate with. Encounters expected by
the GPs to be challenging, and therefore possibly of
interest regarding treatment negotiations, may be
underrepresented.
236 J. HULTBERG AND C. V. RUDEBECK
It can be argued that important information was
missed when only audio and not video was recorded.
The participants’ orientation towards the electronic
health record was audible for example through key-
board clicking, and videouptake may have revealed
non-verbal interactional activity during pauses. The
recordings were of good quality, and we found the
data sufficient for the present analysis. An advantage
with audiorecordings is that they inflict minimally on
clinical encounters, which facilitated the collection of
this relatively large material.
The Swedish primary care setting may limit inter-
national transferability of the results due to the local
health care culture, such as longer visits than in most
other countries, and certain aspects of the Swedish
language. Considering the consistency of our findings
with previous studies, local traditions don’t seem to
have a fundamental impact on the communicative
patterns under study. The frequent use of “one” in
Swedish, and its importance in the allocation of
responsibility and agency in decision-making may not
be transferable to languages where pronouns are used
differently [20]. On the other hand, although a typical
Swedish communicative practice, it accomplishes
renouncement of responsibility and agency in deci-
sion-making, which is a general phenomenon [5,21].
Discussion of results
We focussed on patient resistance in treatment discus-
sions. It should not be read as our understanding that
doctors in general try to persuade patients to take
medication, and patients in general ideally should
resist it.
Within the analyses, we present an overview of the
responses from the GPs to resistance from patients
towards treatment proposals. For the purpose of the
present study, these responses served as an analytical
tool to find sequences that the participants treated as
resistance. Further exploration with an analytical focus
on physicians’ (re-)actions such as in [19] may render
interesting results but is beyond the scope of this
paper.
Patients’ communicative resources are likely avail-
able as potential tools to exert agency also when they
accept treatment proposals. Evaluations merely focus-
ing on physicians’ skills to involve patients, may over-
look patients’ potential and actual exertion of agency,
and erroneously interpret decisions as not being
shared.
Patients’ withholdment of responses, minimal
acknowledgements and weak agreements (passive
resistance), counterproposals and asking questions
(active resistance) following treatment proposals from
physicians has been described [8–10]. These findings
were based on American data from pediatrics, oncol-
ogy and general internal medicine, and mainly but not
solely from out patient clinics. The presence of the
same mechanisms in our data confirms the universality
of these forms of resistance as communicative resour-
ces for patients to exert agency in treatment decision-
making. Cardiovascular preventive drug prescribing
does not seem to be an exception in this regard.
Neither does it emerge as a particular type of treat-
ment decision-making, although it is depicted so in
guidelines for cardiovascular prevention with the advo-
cacy of systematic communication of risk The call for
shared decisions based on risk algoritms is stated both
in current guidelines, and those applicable during data
collection for this study [1,2].
Passive resistance, such as withheld response,
appears as a forceful interactional tool in comparison
with the active modes with regard to the GPs’
responses. This underlines the importance of recogni-
tion and attentiveness to the paradoxically more sub-
tle active resistance in clinical practice and education.
To ask questions is to claim power. It calls for a par-
ticular response, restricts the topic and requests infor-
mation [17]. When posed in response to a treatment
proposal, questions constitute resistance, and are a
way for patients to exert agency. Patients’ disclosures
of “misdeeds” such as changing dose or not taking
medication also show their agency in treatment nego-
tiations. “Misdeeds” have been described to be a way
to initiate treatment negotiations [18]. We argue that
the mechanism at play here is resistance.
The presentation of self is a basic social activity
[15]. Patients’ presentation of self as being someone
who does not take medication implies that starting
with medication would alter identity. In fact, GP con-
sultations may support patients’ change in self-precep-
tion necessary to accept disease, and in the extension,
to accept long-term medication [22]. From the patient
perspective, starting with long-term medication seems
to have a strong influence on self-perception. Our
data confirm that patients express this in treatment
discussions. GPs need to be aware of the effects on
patients’ self-perception from the initiation of long-
term medication, and responsive to patients who
express concern about these effects.
The formulation of treatment proposals often fol-
lows the pattern: “I think we… ” [16,23]. This has
been suggested to constitute “partnership talk” aiming
to obtain consent for the proposal rather than genuine
invitations for participation in decision-making [23].
We found contests of an ambiguous address, the
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tentative inclusive “we”, in treatment proposals.
Apparently, patients not only have communicative
resources to take on agency in decision-making but
also to refrain from it, and the responsibility of being
a decisional agent. Switching from “we” to “one” may
serve to renounce responsibility in treatment negotia-
tions. It is an example of how patients negotiate who
decides, in addition to negotiating the decision.
The impersonal “one” has been described to be
used by Swedish phycisians in an ambiguous way,
with the potential to mean health care provider/-s
including or excluding the patient [20]. GP’s use of
one, referring to the medical expert community, is a
variant of “health care providers in general excluding
the patient” which seems to distance the GP from per-
sonal responsibility. In the literature about patient
power, the notion that patients and physicians com-
pete to claim power is prevailing. In recommendations
for physicians to practice shared decision-making,
maximal patient participation is often portrayed as an
ideal. Our results, in accordance with recent conversa-
tion analytical work, suggest that patients do not
always want to decide, or take responsibility for deci-
sions [5,20,24]. This makes GPs’ deferral of responsibil-
ity and decisional authority problematic. Although it
seemingly allocates power from GPs to patients,
it may not empower patients. On the contrary, it
may pose a threat to the asymmetry in
patient–doctor interaction that “lies at the heart of the
medical enterprise: it is founded in what doctors are
there for” [25].
Unlike the passive forms of resistance – to withhold
response and give weak acknowledgement – active
resistance was found both in response to treatment
proposals, but also preceeding them. The latter may
be regarded as anticipatory resistance, in analogy with
the anticipatory answers to life style questions in
check-ups for chronic conditions in primary care. It
may serve to seize power over the problem definition,
and subsequently influence the solutions, thereby con-
stituting patient agency in decision-making [26].
Anticipatory resistance and postponed decisions
indicate that the time frame for decision-making
extends both the treatment negotiation phase in clin-
ical encounters, and beyond the individual encounter.
This has been discussed as problematic in studies of
decision-making [27,28]. It is important to be aware
of the extended nature of treatment decision-making
in research as well as education in communication
skills. The extension of decision-making beyond indi-
vidual encounters underpins the importance of con-
tinuity of care for sound decision-making about
treatments.
Conclusions
Active and passive resistance to treatment proposals
from GPs displays one mode of how patient agency,
and the subsequent sharing of decision-making, can
be accomplished in clinical encounters.
In clinical practice, education and research about
patient–doctor communication about cardiovascular
preventive medication we propose particular attentive-
ness to patient agency through anticipatory resistance,
patients’ disclosures of non-adherence and presenta-
tions of themselves as non-drugtakers.
The decision-making process about cardiovascular
preventive treatment expands beyond single encoun-
ters. This decision-making in on-going conversations
between patients and GPs underlines the importance
of continuity of care, particularly for the use of long-
term treatments such as cardiovascular preventive
medication.
The sharing of decisions includes a negotiation of
who is the decision-maker. Sometimes GPs and
patients mutually defer responsibility for decisions
through their use of pronouns. Further exploration of
how renouncement of agency in decision-making is
accomplished may provide clinically useful knowledge.
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